Joanna Malicka

Joanna Malicka

Auto-generated profile, based on publicly available information

Joanna Malicka

Department of Endocrinology , Medical University of Lublin , Lublin , Poland

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Family Medicine & Primary Care Review
Verified
Journal Article
Open access
MDMarta Dudzińska
Marta Dudzińska
MNMonika Neć
Monika Neć
AZAgnieszka Zwolak
Agnieszka Zwolak
AOAnna Oszywa-Chabros
Anna Oszywa-Chabros
JMJoanna Malicka
Joanna Malicka
JTJerzy S. Tarach
Jerzy S. Tarach
Background. Understanding the principles of prophylaxis, and awareness of the importance of proper nutrition in maintaining wellbeing should be a part of every doctor–patient relationship. Objectives . An evaluation of the sources of knowledge and access to information about healthy...

21 July 2021 in Journal of Pediatric Endocrinology and Metabolism
Verified
Journal Article
Closed access
EMElżbieta Moszczyńska
Elżbieta Moszczyńska
WGWiesława Grajkowska
Wiesława Grajkowska
MMMaria Maksymowicz
Maria Maksymowicz
JMJoanna Malicka
Joanna Malicka
MSMieczysław Szalecki
Mieczysław Szalecki
MPMonika Prokop-Piotrkowska
Monika Prokop-Piotrkowska
Objectives: To describe the case of a 12-year-old girl with a rare plurihormonal pituitary macroadenoma secreting prolactin (PRL), growth hormone (GH), thyroid-stimulating hormone (TSH), and alpha subunit (α-SU). Case presentation: The patient experienced recurrent headaches and progressing loss of vision in one eye. During the examination, abnormalities such as tall stature, coarse facial features, enlarged feet and hands, tachycardia, hand tremor, hyperhidrosis, galactorrhea, and goiter were observed. Head magnetic resonance imaging (MRI) revealed a solid tumor in the anterior and middle cranial fossa, measuring 80 × 50 × 55 mm. A stereotactic biopsy revealed plurihormonal Pit-1 positive pituitary adenoma secreting PRL, GH, and TSH. A pituitary hyperfunction with PRL, GH, TSH, and α-SU excess was diagnosed. The patient was successfully treated pharmacologically with dopamine agonists and somatostatin analogue, and a decrease of tumor volume (30%) was achieved. Conclusions: When neurosurgery is not possible, long-term pharmacological treatment of plurihormonal pituitary macroadenoma can be a safe and relatively effective alternative.

28 September 2020 in Journal of Medical Science
Verified
Journal Article
Open access
AMAdam Malicki
Adam Malicki
JMJoanna Malicka
Joanna Malicka
EPEmilia Potembska
Emilia Potembska
AZAgnieszka Zwolak
Agnieszka Zwolak
DMDariusz Malicki
Dariusz Malicki
PRPatrycja Rogowska
Patrycja Rogowska
Aim. The study aimed to evaluate the influence of acromegaly on the prevalence and the severity of depressive symptoms in patients with active and inactive disease. Material and Methods. The study group comprised 56 patients with acromegaly, which were divided into two groups based on growth hormone (GH) and insulin-like growth factor (IGF-1) levels, with controlled/cured and with uncontrolled acromegaly. The presence and severity of depressive symptoms were assessed using the Beck Depression Inventory-II (BDI-II). Results. The mean score of BDI-II in the whole group of patients was 13.43±10.41, with no significant difference in the severity of depressive symptoms between patients with cured/controlled and uncontrolled acromegaly (p=0.620). Similarly, the lack of statistically significant differences was confirmed in patients with micro- and macroadenomas, as well as with and without hypopituitarism. There were no significant correlations between BDI-II scores and GH or IGF-1 levels, patient age or duration of the illness. Conclusions. Depressive symptoms are common in acromegalic patients even if remission has been attained. They are most likely caused by psychological, non-organic causes. Patients diagnosed with acromegaly should undergo a screening BDI test as a part of comprehensive care, and in the event of elevated levels should be provided with a psychiatric consultation and psychological care.